Literature DB >> 12714562

VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses.

Tuomas T Rissanen1, Johanna E Markkanen, Marcin Gruchala, Tommi Heikura, Antti Puranen, Mikko I Kettunen, Ivana Kholová, Risto A Kauppinen, Marc G Achen, Steven A Stacker, Kari Alitalo, Seppo Ylä-Herttuala.   

Abstract

Optimal angiogenic and lymphangiogenic gene therapy requires knowledge of the best growth factors for each purpose. We studied the therapeutic potential of human vascular endothelial growth factor (VEGF) family members VEGF-A, VEGF-B, VEGF-C, and VEGF-D as well as a VEGFR-3-specific mutant (VEGF-C156S) using adenoviral gene transfer in rabbit hindlimb skeletal muscle. The significance of proteolytic processing of VEGF-D was explored using adenoviruses encoding either full-length or mature (DeltaNDeltaC) VEGF-D. Adenoviruses expressing potent VEGFR-2 ligands, VEGF-A and VEGF-DDeltaNDeltaC, induced the strongest angiogenesis and vascular permeability effects as assessed by capillary vessel and perfusion measurements, modified Miles assay, and MRI. The most significant feature of angiogenesis induced by both VEGF-A and VEGF-DDeltaNDeltaC was a remarkable enlargement of microvessels with efficient recruitment of pericytes suggesting formation of arterioles or venules. VEGF-A also moderately increased capillary density and created glomeruloid bodies, clusters of tortuous vessels, whereas VEGF-DDeltaNDeltaC-induced angiogenesis was more diffuse. Vascular smooth muscle cell proliferation occurred in regions with increased plasma protein extravasation, indicating that arteriogenesis may be promoted by VEGF-A and VEGF-DDeltaNDeltaC. Full-length VEGF-C and VEGF-D induced predominantly and the selective VEGFR-3 ligand VEGF-C156S exclusively lymphangiogenesis. Unlike angiogenesis, lymphangiogenesis was not dependent on nitric oxide. The VEGFR-1 ligand VEGF-B did not promote either angiogenesis or lymphangiogenesis. Finally, we found a positive correlation between capillary size and vascular permeability. This study compares, for the first time, angiogenesis and lymphangiogenesis induced by gene transfer of different human VEGFs, and shows that VEGF-D is the most potent member when delivered via an adenoviral vector into skeletal muscle.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12714562     DOI: 10.1161/01.RES.0000073584.46059.E3

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  107 in total

1.  VEGF protein in human ischemic skeletal muscle.

Authors:  Martin Flück; Thomas Gustafsson
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

Review 2.  Head and neck lymphatic tumors and bony abnormalities: a clinical and molecular review.

Authors:  Karthik Balakrishnan; Mark Majesky; Jonathan A Perkins
Journal:  Lymphat Res Biol       Date:  2011       Impact factor: 2.589

Review 3.  The lymphatic vasculature in disease.

Authors:  Kari Alitalo
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

Review 4.  Macrophages: An Inflammatory Link Between Angiogenesis and Lymphangiogenesis.

Authors:  Bruce A Corliss; Mohammad S Azimi; Jennifer M Munson; Shayn M Peirce; Walter L Murfee
Journal:  Microcirculation       Date:  2016-02       Impact factor: 2.628

5.  Candesartan induces a prolonged proangiogenic effect and augments endothelium-mediated neuroprotection after oxygen and glucose deprivation: role of vascular endothelial growth factors A and B.

Authors:  Sahar Soliman; Tauheed Ishrat; Anilkumar Pillai; Payaningal R Somanath; Adviye Ergul; Azza B El-Remessy; Susan C Fagan
Journal:  J Pharmacol Exp Ther       Date:  2014-03-28       Impact factor: 4.030

6.  Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision.

Authors:  Claus Cursiefen; Lu Chen; Magali Saint-Geniez; Pedram Hamrah; Yiping Jin; Saadia Rashid; Bronislaw Pytowski; Kris Persaud; Yan Wu; J Wayne Streilein; Reza Dana
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-18       Impact factor: 11.205

7.  VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis.

Authors:  Fan Zhang; Zhongshu Tang; Xu Hou; Johan Lennartsson; Yang Li; Alexander W Koch; Pierre Scotney; Chunsik Lee; Pachiappan Arjunan; Lijin Dong; Anil Kumar; Tuomas T Rissanen; Bin Wang; Nobuo Nagai; Pierre Fons; Robert Fariss; Yongqing Zhang; Eric Wawrousek; Ginger Tansey; James Raber; Guo-Hua Fong; Hao Ding; David A Greenberg; Kevin G Becker; Jean-Marc Herbert; Andrew Nash; Seppo Yla-Herttuala; Yihai Cao; Ryan J Watts; Xuri Li
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-06       Impact factor: 11.205

8.  VEGF-D: a modifier of embryonic lymphangiogenesis.

Authors:  Terhi Karpanen; Kari Alitalo
Journal:  Blood       Date:  2008-09-01       Impact factor: 22.113

9.  Vascular endothelial growth factor D is dispensable for development of the lymphatic system.

Authors:  Megan E Baldwin; Michael M Halford; Sally Roufail; Richard A Williams; Margaret L Hibbs; Dianne Grail; Hajime Kubo; Steven A Stacker; Marc G Achen
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

10.  Activated forms of VEGF-C and VEGF-D provide improved vascular function in skeletal muscle.

Authors:  Andrey Anisimov; Annamari Alitalo; Petra Korpisalo; Jarkko Soronen; Seppo Kaijalainen; Veli-Matti Leppänen; Michael Jeltsch; Seppo Ylä-Herttuala; Kari Alitalo
Journal:  Circ Res       Date:  2009-05-14       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.